Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K31/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.202022106782Antiurolithiatische, antiosteoporotische, antidiabetische und entzündungshemmende Zusammensetzung eines Polykräuterextraktes
DE 26.01.2023
Int.Class A61K 36/59
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18Magnoliophyta (angiosperms)
185Magnoliopsida (dicotyledons)
59Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
Appl.No 202022106782 Applicant Azeemuddin Mohammed Inventor

Antiurolithiatische, antiosteoporotische, antidiabetische und entzündungshemmende Polykräuterextrakt-Zusammensetzung, umfassend: a) 100 mg Tinospora sinensis Stamm; b) 150 mg Moringa oleifera-Wurzelrinde; c) 250 mg Acacia sinuata-Schoten; d)Chondroitinsulfat(Standardarzneimittel); e) 0,75 % Ethylenglykol, wobei die Mischung aus wässrigem Extrakt aus Acacia sinuata-Schoten, methanolischem Extrakt aus Moringa oleifera-Wurzelrinde und ethanolischem Extrakt aus Tinospora sinensis-Stämmen im Verhältnis 1:2: 1 besteht und gegen Ethylenglykol-induzierte Urolithiasis, Diabetes, Entzündungen und Osteoporose wirkt, wobei 400mg/kg und 200mg/kg als hohe und niedrige Dosis gewählt wurden.

2.WO/2023/001607MICRONEEDLE ARRAY WITH ANTISEPTICS
WO 26.01.2023
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
Appl.No PCT/EP2022/069218 Applicant LTS LOHMANN THERAPIE-SYSTEME AG Inventor WINTERBERG, Markus
The present invention relates to a microneedle array for use in the intradermal application of active substances, the array comprising a plurality of microneedles on a support which are formed of a formulation that contains a biodegradable polymer, an active substance and an antiseptic.
3.WO/2023/003122COMPOSITION FOR INHIBITING CORONAVIRUS PROLIFERATION
WO 26.01.2023
Int.Class A61K 31/353
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
352condensed with carbocyclic rings, e.g. cannabinols, methantheline
3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
Appl.No PCT/KR2022/003907 Applicant BEN'S LAB CO., LTD. Inventor JEONG, Jong Moon
The present invention relates to a composition for inhibiting coronavirus proliferation, comprising epigallocatechin gallate (EGCG) as an active ingredient, the composition being applicable locally to the oral cavity, nasal cavity, or the like, thus inhibiting the proliferation of coronavirus that causes respiratory diseases in epithelial cells of the oral cavity, nasal cavity, or the like, and consequently being capable of preventing respiratory diseases or inhibiting the progression of respiratory diseases into the severe stage.
4.WO/2023/002252COMPOSITION COMPRISING BETA-GLUCANS AND ALPHA-FUCANS FOR IMPROVING GUT HEALTH AND ANIMAL PERFORMANCE AND METHODS OF MAKING THE SAME
WO 26.01.2023
Int.Class A61K 31/716
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
716Glucans
Appl.No PCT/IB2022/000421 Applicant BIOATLANTIS LIMITED Inventor O'DOHERTY, John
The present invention relates to a composition and methods comprising an amount of β-glucans and α-fucans, wherein the combination is synergistic to at least one of: increase growth of beneficial microbes and reduced levels of harmful microbes selected from E. coli or Salmonella in animal or human intestines, improve gut structure, reduce gut inflammation, improved nutrient digestibility, improve mineral absorption and growth performance, or reduce gut infection and inflammation.
5.WO/2023/002222COMPOSITIONS COMPRISING DOPED SILICON PARTICLES, AND RELATED METHODS
WO 26.01.2023
Int.Class A61K 8/25
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
8Cosmetics or similar toilet preparations
18characterised by the composition
19containing inorganic ingredients
25Silicon; Compounds thereof
Appl.No PCT/GB2022/051937 Applicant SISAF LTD Inventor SAFFIE-SIEBERT, Roghieh Suzanne
A pharmaceutical composition comprising particles comprising hydrolysable doped silicon and one or more lipids complexed with an active pharmaceutical ingredient, wherein the particles are doped at a level of at least 1 x1016 dopant atoms per cm3. Also related products, methods, and medical uses.
6.WO/2023/002192AEROSOL GENERATION AND DELIVERY SYSTEM FOR CARBOXYLATED ACTIVES
WO 26.01.2023
Int.Class A24F 40/30
AHUMAN NECESSITIES
24TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
FSMOKERS’ REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
40Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
30Devices using two or more structurally separated inhalable precursors, e.g. using two liquid precursors in two cartridges
Appl.No PCT/GB2022/051892 Applicant NICOVENTURES TRADING LIMITED Inventor STROPHAIR, Oriol
The present invention relates to a delivery system comprising a powered aerosol generating device and an aerosolisable material, wherein the powered aerosol generating device comprises a power source and a controller, and the system comprises a first aerosolisable material and a second aerosolisable material, wherein the second aerosolisable material comprises at least one carboxylated active and is stored in the system separately from the first aerosolisable material.
7.WO/2023/003002ANNULATED PYRIDAZINE COMPOUND
WO 26.01.2023
Int.Class C07D 237/32
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
237Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
26condensed with carbocyclic rings or ring systems
30Phthalazines
32with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
Appl.No PCT/JP2022/028138 Applicant ASTELLAS PHARMA INC. Inventor INAGAKI, Yusuke
The present invention addresses the problem of providing a pharmaceutical composition, in particular, a compound suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases. The inventors of the present invention conducted extensive studies to find a compound that has an inhibiting action on NLRP3 inflammasome activation, and found that an annulated pyridazine compound has an inhibiting action on NLRP3 inflammasome activation, leading to the achievement of the present invention. The annulated pyridazine compound according to the present invention is expected to serve as a drug for preventing and/or treating inflammatory diseases and/or a neurodegenerative diseases.
8.WO/2023/003497COMPOUNDS WITH LYSOSOMOTROPIC AND ANTIVIRAL ACTIVITY
WO 26.01.2023
Int.Class A61K 31/4523
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
Appl.No PCT/RU2022/050229 Applicant LTD "VALENTA-INTELLEKT" Inventor VLADYKIN, Aleksandr Lvovich
The invention relates to the field of pharmacology, and more particularly to compounds with lysosomotropic activity. Proposed is the use of known chemical compounds as agents with lysosomotropic and antiviral activity. The present invention further relates to pharmaceutical compositions and medicaments containing said compounds with lysosomotropic activity. The property of selective accumulation in lysosomes, discovered for said compounds, lends them potential as antiviral agents for the treatment and/or prophylaxis of viral infections, including viral respiratory infections such as influenza, which act on the pH-dependent stages taking place in intracellular structures (the lysosomal apparatus, the endoplasmic reticulum and the Golgi apparatus) during the life cycle of viruses spread by the airborne or fecal-oral route.
9.WO/2023/001982MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION
WO 26.01.2023
Int.Class G01N 33/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Appl.No PCT/EP2022/070541 Applicant UNIVERSITÄT BASEL Inventor FLOHR, Alexander
The present invention relates to ligands specifically presented by MR1 molecules to MR1-specific T cells. These ligands are derivatives or analogues of nucleic acid forming bases, particularly ribonucleoside and deoxyribonucleoside adducts occurring in eukaryotic cells under certain conditions. The invention further relates to pharmaceutical preparations and methods for use of such ligands in treatment and research. The invention further relates to pharmaceutical preparations provided with the aim of modulating presentation of MR1 ligands in clinical situations where such modulated presentation of MR1 ligands is of clinical benefit.
10.WO/2023/001247PYRIDAZINONE COMPOUND
WO 26.01.2023
Int.Class C07D 403/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
14containing three or more hetero rings
Appl.No PCT/CN2022/107127 Applicant MEDSHINE DISCOVERY INC. Inventor FU, Xiangyu
A series of pyridazinone compounds and pharmaceutically acceptable salts thereof, and an application thereof in the preparation of a drug for treating a related disease. Specifically disclosed are a compound of formula (IV) and a pharmaceutically acceptable salt thereof.